Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192057 | 0.96 | CRHR1 (0.47) | CRHR1HDAC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2192347 | 0.93 | CRHR1 (0.48) | CRHR1HDAC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5571630 | 0.89 | CRHR1 (0.46) | CRHR1HDAC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2193130 | 0.88 | CRHR1 (0.46) | CRHR1HDAC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2192145 | 0.88 | CRHR1 (0.47) | CRHR1HDAC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3281391 | 0.87 | CRHR1 (0.42) | CRHR1HDAC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2189300 | 0.86 | CRHR1 (0.43) | CRHR1HDAC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3275570 | 0.85 | CRHR1 (0.45) | CRHR1HDAC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3275565 | 0.85 | CRHR1 (0.45) | CRHR1HDAC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3281376 | 0.85 | CRHR1 (0.40) | CRHR1HDAC1ALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618107-B1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-06-30 | — | — | EP | disclosed |
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR1, NR3C2, CRHR2 | CRHR1 1/4885HDAC1 920/4885CYP11B1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.